{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Number of participants who are in complete remission (CR) 4 weeks after transplant. CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:\n\n1. Normal bone marrow with blasts \\<5% with normal cellularity, normal megakaryopoiesis, \\> 15% erythropoiesis and \\> 25% granulocytopoiesis\n2. Normalization of blood counts (no blasts, platelets \\> 100000/mm3, granulocytes \\>1500/mm3)\n3. No extramedullary disease.","groups":[{"description":"PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)","id":"OG000","title":"Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Study participants who completed the study regimen","reportingStatus":"POSTED","timeFrame":"4 weeks after transplant","title":"Achievement of Remission","type":"SECONDARY","unitOfMeasure":"Participants"}